
In today’s ACT Brief, we examine how China’s trial startup timelines compare with those in the US and Europe, whether AI-drafted clinical study reports speed drug development, and how Bimzelx compared with Skyrizi in psoriatic arthritis.
Mike Rousselle, Vice President of Data Product for OptimizeRx, discusses his serendipitous career, current role, how the company ties AI and RWE together for trial recruitment, and more.






